929 results about "Myocardial cell" patented technology

The invention discloses application of an RNF130 activator in preparation of a medicine for preventing and / or treating ischemic heart disease, and belongs to the technical field of biological medicine. Research results show that when an RNF130 activator is given in a mouse of a myocardial ischemia reperfusion injury model, the left ventricular ejection fraction and the left ventricular short-axis shortening rate of the mouse can be improved, myocardial tissue pathological injury can be relieved, the protein expression levels of NOX-2, BAX and TNF-alpha are reduced, the myocardial infarction area is reduced, and myocardial cell apoptosis is reduced; therefore, the RNF130 activator has prevention and treatment effects on the myocardial ischemia-reperfusion injury, that is, the RNF130 activator can be used as an effective component of the medicine for preventing or treating diabetes complicated by myocardial ischemia-reperfusion injury, and a new strategy is provided for preparation of the medicine for preventing and treating myocardial ischemia-reperfusion injury.

The invention relates to the technical field of spermidine application, in particular to application of spermidine in preparation of medicine for preventing and treating doxorubicin-induced cardiotoxicity and myocardial aging. Cell proliferation experiments and mouse survival rate experiments show that spermidine can reduce death of myocardial cells and mice caused by adriamycin; a q-PCR experiment shows that spermidine can improve abnormal expression conditions of P53, P21, P16, BAX, TNF-alpha, IFN alpha, IL-10 and IL-18 in myocardial cells caused by adriamycin; a beta-galactosidase staining experiment shows that the spermidine can reduce the condition that the expression of a marker beta-galactosidase for myocardial cell senescence induced by adriamycin is increased; a Western Blot experiment shows that the spermidine can improve the condition that the P53 protein is abnormally increased due to the adriamycin; an Elisa experiment shows that spermidine can improve the condition that myocardial injury markers cTn-I and AST and inflammatory factors IL-1beta are abnormally increased due to adriamycin, and the myocardial injury markers cTn-I and AST and inflammatory factors IL-1beta are abnormally increased due to adriamycin. Therefore, spermidine can improve cardiotoxicity and myocardial aging induced by adriamycin.

The invention discloses a compound composition with a multi-target heart protection function as well as a preparation method and application of the compound composition. The composition is composed of a basic functional oil phase, a core antioxidant / anti-inflammatory phase, a myocardial nutrition and regulation phase and a bioavailability promotion phase in a synergistic manner, and is integrated into a composite cardiac oligopeptide and microencapsulated particle key component substance through a specific enzymolysis and microencapsulation embedding process system. The invention aims to solve the technical problems of single target spot, insufficient synergistic effect of all components, low bioavailability of active components and poor stability of the existing heart protection product, and provides a stable and easily-absorbed composite composition which can realize synergistic effect from multiple channels at the same time. Technical effect verification shows that under the condition of equal-dose sample feeding, the composition can remarkably improve the bioavailability of functional components and shows excellent myocardial cell oxidative damage resistance and myocardial ischemia improvement activity in cell and animal models, the effect is remarkably superior to that of independent use or simple physical mixing of all the components, and the composition is suitable for clinical application. And the substantial progress of synergistic interaction is proved. The composition can be used for developing various medicines, health foods and functional foods beneficial to heart health.

The invention discloses application of chrysin-7-0-beta-D-glucuronide in treatment of ischemic heart disease or an LRP6 inhibitor, and belongs to the technical field of treatment of ischemic heart disease. The invention provides a new application of a small molecular compound chrysin-7-0-beta-D-glucuronide, the compound realizes regulation and control on a cardiac muscle cell cycle by inhibiting LRP6, and finally promotes repair of cardiac muscle cells and inhibits apoptosis. According to the invention, by exploring the function of inhibiting LRP6 protein of a small molecule drug, a powerful repair reaction is guided after myocardial ischemia reperfusion, so that effective treatment of myocardial infarction is realized. Therefore, finding of an LRP6 inhibitor not only has a potential curative effect on promoting myocardial cells to enter a cell cycle, but also has important significance on treatment of MI.

The invention discloses application of enterococcus pluvialis and exosomes thereof, and relates to the field of application of enterococcus pluvialis and exosomes thereof. The enterococcus pluvialis disclosed by the invention is enterococcus pluvialis Zz-2024, is preserved in the General Microbiological Culture Collection Center of the China Committee for Culture Collection of Microorganisms, and has a preservation number of CGMCC (China General Microbiological Culture Collection Center) No. 31249. The invention relates to an exosome produced by Enterococcus pluvialis Zz-2024, and an application of the exosome in a medicine for treating myocarditis, and particularly relates to an exosome produced by Enterococcus pluvialis Zz-2024 and an application of the exosome in a medicine for treating myocarditis. The enterococcus pluvialis exosome disclosed by the invention has excellent effects in experiments of inhibiting myocarditis factors, reducing lipid droplet aggregation, inhibiting myocardial cell senescence and the like, and breaks through the limitation that human stem cell source exosomes are adopted in related fields at present.

The invention belongs to the field of biological medicines, and particularly discloses application of DNAJB6 in preparation of medicines for preventing or treating myocardial infarction (MI). In-vivo and in-vitro experiments find that the expression of DNAJB6 protein in an MI model is remarkably reduced, and the over-expression of DNAJB6 can improve the cardiac function of a mouse after MI, relieve myocardial fibrosis and inhibit hypoxia-induced myocardial apoptosis; and cell apoptosis is aggravated by low expression of DNAJB6. The overexpression of the DNAJB6 by using the myocardial specific adeno-associated virus (AAV) can be used as a new strategy for preventing and treating the MI, and an experimental basis is provided for developing a drug for targeting the DNAJB6.

The invention belongs to the technical field of biological medicines, and particularly relates to application of oxibenzophenone in preparation of a medicine for treating pathological cardiac hypertrophy and / or heart failure. Research results in myocardial cells of primary newborn rats show that Exibenzophenone can inhibit pathological hypertrophy of myocardial cells induced by phenylephrine (PE). Animal experiments show that the epoxybenzophenone can improve cardiac dysfunction induced by aortic arch constriction (TAC) and reduce cardiac hypertrophy and cardiac tissue fibrosis. The invention provides a new drug research and development approach and a drug action target for treating pathological cardiac hypertrophy and heart failure, and has very important medicinal value.

The invention relates to application of an MYZAP overexpression vector in preparation of a medicine for preventing and treating MIRI, and belongs to the technical field of biological medicine. In order to solve the problem that application of gene drugs in prevention and treatment of myocardial ischemia reperfusion injury is limited, the invention provides application of an MYZAP gene overexpression recombinant vector in preparation of drugs for prevention and treatment of myocardial ischemia reperfusion injury, and the MYZAP gene overexpression recombinant vector is an adeno-associated virus vector AAV9-MYZAP for overexpressing MYZAP. Experiments prove that MYZAP overexpression can improve the cardiac function after myocardial ischemia reperfusion, reduce the occurrence rate of arrhythmia and improve the functions of sodium ion channels, potassium ion channels and calcium ion channels of myocardial cells. On the basis, the invention further provides a medicine for preventing and treating myocardial ischemia reperfusion injury, a new strategy is provided for gene therapy of myocardial ischemia reperfusion injury, and the medicine has a wide clinical application prospect.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a composition for resisting doxorubicin cardiotoxicity and a preparation method, application and a preparation thereof. The invention provides a composition capable of resisting doxorubicin cardiotoxicity, the composition comprises diosmetin and loureirin B, the diosmetin and the loureirin B can be extracted through natural plants, the raw materials are low in cost and easy to obtain, and clinical popularization and application are facilitated. The cell experiment research finds that the combined administration of diosmetin and loureirin B can significantly improve the survival rate of adriamycin-damaged myocardial cells and significantly reduce the active oxygen level and positive cell rate, and verifies the synergistic interaction of diosmetin and loureirin B in resisting adriamycin cardiotoxicity.

The invention belongs to the field of medicines, and relates to a compound derived from Sinkiang lithospermum, a preparation method thereof and application of the compound in prevention and treatment of cardiovascular diseases. Specifically, the invention discloses a monoterpene benzoquinone derivative with a novel structure in Sinkiang lithospermum, a preparation method of the monoterpene benzoquinone derivative and application of the compound in preparation of anti-myocardial injury drugs. An in-vitro anti-myocardial cell injury activity experiment proves that the compound has a remarkable protection effect on isoprenaline (ISO)-induced H9C2 cell (rat embryo myocardial cell) injury and hypoxia-reoxygenation-induced H9C2 myocardial cell injury. The result shows that the compound can be used for preparing the anti-cardiovascular disease medicine.

The invention provides a dilated cardiomyopathy zebrafish model and a construction method and application thereof, and belongs to the technical field of biology.The dilated cardiomyopathy zebrafish model is constructed by overexpressing miR-16-5p in myocardial cells of zebrafish, and the sequence of miR-16-5p is shown as SEQ ID NO.1; the invention further provides a construction method of the dilated cardiomyopathy zebra fish model. The invention constructs the dilated cardiomyopathy zebrafish model of overexpression miR-16-5p in myocardial cells for the first time, and the dilated cardiomyopathy zebrafish model can be used for screening drugs for resisting dilated cardiomyopathy.

The invention relates to the technical field of traditional Chinese medicine carbon dots, in particular to ligusticum wallichii carbon dots, a medicine and application. The ligusticum wallichii carbon dots disclosed by the invention are obtained by carbonizing ligusticum wallichii by a hydrothermal method, wherein the hydrothermal method carbonization is a hydrothermal reaction at 175-195 DEG C for 8-12 hours; research finds that the ligusticum wallichii carbon dots have the characteristic of treating myocardial apoptosis caused by myocardial ischemia reperfusion injury, and compared with ligusticum wallichii carbon dots synthesized by ligustrazine and a pyrolysis method, the ligusticum wallichii carbon dots have the advantage that the heart function can be better recovered. The invention provides a new candidate drug for treating myocardial ischemia reperfusion injury.

The invention relates to application of an MYZAP overexpression recombinant vector in preparation of a medicine for preventing and treating arrhythmia, and belongs to the technical field of biological medicines. In order to solve the problem that application of gene drugs in prevention and treatment of arrhythmia after myocardial infarction is limited, the invention provides application of a myocardial microbelt adhesion protein MYZAP overexpression recombinant vector in preparation of drugs for prevention and treatment of arrhythmia, and the MYZAP overexpression recombinant vector is an adeno-associated virus vector AAV9-MYZAP of an overexpression MYZAP gene. In-vivo experiments prove that MYZAP overexpression can reduce the occurrence of arrhythmia after myocardial infarction by increasing the content of MYZAP protein in cardiac myocardial cells, and improve cardiac functions and cardiac electrical conduction disorders after myocardial infarction. On the basis, the invention further provides a medicine for preventing and treating arrhythmia after myocardial infarction, a new strategy is provided for gene therapy of arrhythmia after myocardial infarction, and the medicine has a wide clinical application prospect.

Disclosed in the present invention is a use of alisol-B23-acetate (AB23a) in the preparation of a drug for preventing or treating hypertrophic cardiomyopathy and diseases caused by the hypertrophic cardiomyopathy. The present invention provides for the first time a use of AB23a in the prevention or treatment of hypertrophic cardiomyopathy. According to the present invention, use of AB23a in direct in vitro treatment of cardiomyocytes derived from directed differentiation of human embryonic stem cells revealed that AB23a-based in-vitro treatment can significantly inhibit hypertrophic phenotypes of the human embryonic stem cells-cardiomyocytes; using an AB23a-containing feed to feed mice with hereditary hypertrophic cardiomyopathy caused by a gene mutation revealed that AB23a prominently relieves pathological myocardial hypertrophy of the mice and improves the cardiac function; AB23a can be used for preparing a drug for resisting hereditary hypertrophic cardiomyopathy, offering a novel way and means for treating hypertrophic cardiomyopathy; and AB23a is the main medicinal ingredient in the traditional Chinese medicinal herb-Rhizoma Alismatis, is safe to organisms, and has good clinical application prospects.

The invention relates to the technical field of biological medicines, in particular to a preparation method of extracellular vesicles derived from myocardial cells derived from human induced pluripotent stem cells as well as a product and application of the extracellular vesicles. The method comprises the following steps: pretreating human induced pluripotent stem cell derived myocardial cells (hiPSCs-CMs) by using honokiol, and culturing the treated human induced pluripotent stem cell derived myocardial cells to collect extracellular vesicles (EVs) secreted by the human induced pluripotent stem cell derived myocardial cells. The extracellular vesicles secreted by the myocardial cells derived from the human induced pluripotent stem cells pretreated by honokiol are rich in functional mitochondria, show a better myocardial infarction treatment effect in animal experiments, and have huge clinical potential.

The invention provides a nucleic acid aptamer and a screening method thereof, the aptamer is of an oligonucleotide DNA structure, the nucleotide sequence of the nucleic acid aptamer is the nucleotide sequence of any DNA fragment as shown in SEQ ID NO: 1-9, and the nucleic acid aptamer can specifically target cardiac muscle cells (CMs). According to the invention, a new strategy can be provided for clinical treatment of cardiovascular diseases, and meanwhile, bioactive molecules such as microRNA (miRNA), small interfering RNA (small interfering RNA, siRNA), lipidosome, microspheres, microcapsules and the like can be carried to be used as an intracellular drug delivery tool.

The invention discloses an active exosome stent coating based on traditional Chinese medicine enhanced secretion promotion and a preparation method and application thereof, and belongs to the technical field of biological medicine and interventional instruments. The stent coating comprises exosomes, wherein the exosomes comprise myocardial cell active exosomes and human mesenchymal stem cell active exosomes which are intensified and secreted by traditional Chinese medicines; wherein the traditional Chinese medicines comprise placenta extract, pilose antler extract, sheep myocardial peptide, sea cucumber peptide, lycium ruthenicum peptide, cnidium lactone, curculigo orchioides extract and morinda officinalis extract; the intervention concentration of each component added into cells is 2-50 [mu] g / mL; the light-cured gel matrix is prepared from methacrylated gelatin, a photoinitiator and polyether 127; tacrolimus; the final concentration of the exosome is 1 * 10 < 9 >-12 * 10 < 9 > particles / mL, and the final concentration of the tacrolimus is 5-25 mu g / mL. The coating can be coated on the surface of the poly-L-lactic acid degradable stent to prepare the degradable stent, and has obvious vascular repair promoting capability.

The invention discloses a medicine prepared from apoptotic fibroblast-derived vesicles and used for preventing and treating myocardial ischemia-reperfusion injury as well as a preparation method and application of the medicine, and relates to the technical field of biological medicines. The method comprises the following steps: digesting an in-vitro animal heart apex tissue to obtain a digested cell suspension; the myocardial fibroblasts are obtained; the method comprises the following steps: culturing myocardial fibroblasts in a DMEM (dulbecco's modified eagle medium) solution through apoptosis inducer H2O2 to obtain a culture solution; according to the method, apoptosis of fibroblasts is induced to generate specific extracellular vesicles, the surface of the extracellular vesicles carries CD22 as a marker, the content of the extracellular vesicles is enriched in miR-1246 and is taken by myocardial cells, expression of p53 is down-regulated, mitochondrial homeostasis is maintained, and the extracellular vesicles can be used for detecting apoptosis of the fibroblasts. The myocardial cell apoptosis is inhibited.

The present invention pertains to a polypeptide comprising the amino acid sequence according to SEQ ID NO: 1 or a variant or fragment thereof for use in treating or preventing heart failure, myocardial infarction or hypertrophy, reducing infarct size or scar size after myocardial infarction, inducing endothelial cell sprouting after myocardial infarction, protecting cells from ischemia- or reperfusion-induced injury, promoting angiogenesis after myocardial infarction, promoting coronary endothelial cell migration and proliferation, inhibiting cardiomyocyte hypertrophy, or inhibiting inflammation. The present invention further provides a nucleic acid sequence encoding the polypeptide, vectors comprising the nucleic acid sequence, host cells comprising the nucleic acid or vector, and respective pharmaceutical compositions for the same use.

The invention belongs to the technical field of biology, and particularly relates to a compound for treating myocardial infarction. The chondroitin sulfate oligosaccharide is extracted from natural chondroitin sulfate, and after the chondroitin sulfate oligosaccharide is treated into an oligosaccharide chain through a chemical enzyme method, experiments prove that the chondroitin sulfate oligosaccharide is beneficial to the survival of myocardial cells. Compared with other products with similar functions, the glycopeptide polymer hydrogel formed after introduction of the polymer skeleton overcomes the problem of batch-to-batch difference of natural products and is clear in structure, and the hydrogel has excellent biological activity and does not need to entrap other active ingredients such as drugs. The effects of supporting the ventricular wall of the infarction region and promoting the survival of myocardial cells are obvious, the myocardial infarction area can be effectively limited, the thickness of the ventricular wall of the infarction region is increased, the damage of myocardial infarction to the heart is reduced, and the application prospect is very good.

The invention belongs to the technical field of medicines, and mainly relates to application of 3 ', 4'-dihydroxy flavonol in treatment of hypertension. The invention firstly provides application of 3 ', 4'-dihydroxy flavonol or pharmaceutically acceptable salt thereof in preparation of products for preventing and / or treating hypertension. The invention also provides an application of the 3 ', 4'-dihydroxy flavonol or the pharmaceutically acceptable salt thereof in preparation of a product, and the product is used for reducing blood pressure; the blood vessel function reduction is improved; the blood vessel wall thickening is improved; the heart function reduction is improved; the 3 ', 4'-dihydroxy flavonol can improve any one or more of myocardial cell hypertrophy, and the invention further provides a product which comprises an effective dose of 3 ', 4'-dihydroxy flavonol or pharmaceutically acceptable salt thereof. The application finds that the 3 ', 4'-dihydroxy flavonol and the pharmaceutically acceptable salt thereof can be effectively used for preventing or treating hypertension, and a new way is opened up for the treatment of hypertension or hypertension-related diseases.

The invention discloses an application of pentagalloylglucose (PGG) in preparation of a medicine for resisting doxorubicin cardiotoxicity. The method comprises the following steps: inducing doxorubicin (DOX), establishing a myocardial cell H9C2 injury model, and determining the DOX-induced myocardial cell injury minimum concentration; after 20 [mu] M of PGG is added into a treatment group, DOX-induced H9C2 cell apoptosis can be significantly improved. A mouse myocardial injury model is induced and established by DOX, and compared with a doxorubicin group, the left ventricular systolic fraction (FS%) and ejection fraction (EF%) of mice in the doxorubicin and pentagalloylglucose group are remarkably increased, the myocardial fiber structure is improved, the cytoplasm vacuolation is reduced, the serum cTnT and BNP levels are reduced, and the ROS level is reduced. The experiment proves that the pentagalloylglucose can obviously reduce the cardiotoxicity induced by the DOX.

The invention provides a construction method and application of a dilated cardiomyopathy animal model, belongs to the technical field of biological medicine and animal genetic model construction, and provides a novel dilated cardiomyopathy zebrafish model which is constructed by specifically overexpressing a truncated dnajb6b gene long isomer fragment in zebrafish myocardial cells. The nucleotide sequence of the gene segment is as shown in SEQ ID NO. 1; the invention also provides a construction method and application of the dilated cardiomyopathy zebra fish model, and further discovers application of 4-phenylbutyric acid in preparation of drugs for treating dilated cardiomyopathy.

The invention relates to the field of biomedicine, in particular to application of PXDC1 in preparation of a product for treating myocardial hypertrophy. The invention discloses the effectiveness of inhibiting PXDC1 expression in treating cardiac hypertrophy and controlling the occurrence and development process of the cardiac hypertrophy for the first time. The invention provides a novel drug target and strategy for treating myocardial hypertrophy, and the novel drug target and strategy can reduce the expression of a myocardial hypertrophy biomarker, reduce the size of myocardial cells, improve the ejection fraction and short axis shortening rate of the heart, reduce the weight ratio of the heart and relieve the degree of myocardial fibrosis. Besides, the invention clarifies the action mechanism of PXDC1 in myocardial hypertrophy, deepens the understanding of the pathogenesis of the disease, and lays an important foundation for further exploration of myocardial hypertrophy-related cytobiology and molecular biology processes.

To provide treatment of arrythmia caused by taking of myocardial cells derived from stem cell in methods for treating heart failure.SOLUTION: The invention relates to an antiarrhythmic agent, an antiarrhythmic myocardial cell population, a method for obtaining an antiarrhythmic myocardial cell population by in vitro exposure of stem cell-derived myocardial cells to an antiarrhythmic agent, and / or medical use of antiarrhythmic myocardial cell population in the prevention of arrythmia and in the treatment of heart failure.SELECTED DRAWING: None

The invention provides a hypertrophic cardiomyopathy zebrafish model and a construction method and application thereof, and belongs to the technical field of biology, the hypertrophic cardiomyopathy zebrafish model is constructed by overexpressing miR-29a in myocardial cells of zebrafish, and the sequence of the miR-29a is shown as SEQ ID NO.1; the invention further provides a construction method of the hypertrophic cardiomyopathy zebra fish model. The hypertrophic cardiomyopathy zebrafish model Tg (cmlc2: miR-29a, EGFP) with overexpression of miR-29a in myocardial cells is constructed for the first time, and the hypertrophic cardiomyopathy zebrafish model Tg (cmlc2: miR-29a, EGFP) can be used for screening drugs for resisting hypertrophic cardiomyopathy.

The present invention relates to an adeno-associated virus (AAV) capsid protein variant having an amino acid mutation between the 586 and the 589 relative to a parent AAV capsid protein wherein the mutation is to replace residues at the 587 and the 588 of the parent AAV capsid protein with an amino acid sequence as shown in SEQ ID NO: 5 or 8 wherein the amino acid position is numbered according to SEQ ID NO: 9. The invention also relates to an isolated nucleic acid encoding the AAV capsid protein variant, a nucleic acid vector comprising the same, and a host cell. The invention also relates to a recombinant adeno-associated virus (rAAV) vector comprising said capsid protein variant, a pharmaceutical composition comprising said rAAV vector and its use in the treatment or prevention of cardiovascular diseases.

The invention relates to application of piRNA-AB352916 and a mimetic thereof in preparation of a medicine for treating ischemic heart disease, and belongs to the technical field of medicines. In order to solve the problem that a medicine capable of promoting myocardial cell proliferation and inhibiting myocardial cell apoptosis is lacked in the treatment process of the ischemic heart disease, the invention provides application of piRNA-AB352916 and a mimetic thereof in preparation of a medicine for treating the ischemic heart disease. According to the application disclosed by the invention, the expression level of the piRNA-AB352916 in myocardial regeneration model tissues after cardiac apex resection is obviously increased, and animal experiments prove that the myocardial specific overexpression piRNA-AB352916 not only can promote myocardial cell proliferation, but also can inhibit myocardial cell apoptosis, so that the myocardial infarction area is reduced, and the cardiac function of an infarction mouse is improved. The invention proves that the piRNA-AB352916 and the analogue thereof have prevention and treatment values on the ischemic heart disease.

The invention relates to a myocardial tissue construct with a bionic structure and a function as well as a preparation method and application of the myocardial tissue construct. The myocardial tissue construct with both the bionic structure and the function comprises the following components: a hydrogel matrix suitable for 3D printing rheological properties, a cross-linking agent dispersed in the hydrogel matrix, inorganic biological material particles with myocardial protection and vascularization biological activity promotion, myocardial cells and vascularization related cells, the myocardial cells and the vascularization-related cells are regularly arranged in a three-dimensional space by simulating a cell distribution mode in a natural myocardial tissue; preferably, the regularly arranged structure comprises at least one of spatial arrangement of myocardial cell-angiogenesis related cells in a left-right / up-down side-by-side mode and spatial arrangement of myocardial cell-angiogenesis related cells in a core-shell / shell-core coaxial mode.

The invention discloses application of a Cpeb3 gene inhibitor and a copper death inhibitor in preparation of a medicine for treating myocardial ischemia-reperfusion injury, and relates to the technical field of myocardial ischemia-reperfusion injury. By specifically reducing or knocking out Cpeb3 expression, myocardial repair can be remarkably promoted, action potential stability is improved, and the death rate is reduced. Therefore, Cpeb3 is a specific intervention target spot of copper death in Gpc6 + CMs. The small molecule inhibitor of Cpeb3 can remarkably reverse changes of copper death, aerobic respiration and / or glycolysis caused by Cpeb3 activation. In addition, the copper death inhibitor can improve the survival rate of myocardial cells, reverse the change of aerobic respiration and / or glycolysis induced by Cu, and reverse the change of glycolysis, pentose phosphate pathway and tricarboxylic acid cycle metabolites caused by Cu stimulation. Therefore, the invention provides a new solution for prevention and treatment of myocardial ischemia reperfusion injury, and has a good application prospect.